Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.1%

233 terminated/withdrawn out of 1656 trials

Success Rate

83.8%

-2.7% vs industry average

Late-Stage Pipeline

41%

687 trials in Phase 3/4

Results Transparency

39%

464 of 1205 completed trials have results

Key Signals

55 recruiting464 with results178 terminated55 withdrawn

Enrollment Performance

Analytics

Phase 2

450(29.6%)

Phase 3

383(25.2%)

Phase 1

315(20.7%)

Phase 4

304(20.0%)

N/A

58(3.8%)

Early Phase 1

9(0.6%)

1519Total

Phase 2(450)

Phase 3(383)

Phase 1(315)

Phase 4(304)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1656)

Showing 20 of 1656 trials

NCT01712581Not ApplicableCompleted

Heart Map Study -Determination of Myocardial Relaxation Times Values in Healthy Volunters

Role: collaborator

NCT07025512Phase 2Suspended

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

Role: collaborator

NCT04028245Early Phase 1Completed

A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma

Role: collaborator

NCT01642017Phase 1Terminated

Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria

Role: collaborator

NCT05622929Not ApplicableCompleted

Cluster Randomized Trial of a Digital Quality Improvement Intervention on LDLCholesterol Control

Role: collaborator

NCT04239157Phase 2Recruiting

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Role: collaborator

NCT05518110Phase 2Terminated

PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer

Role: collaborator

NCT01623167Phase 1Active Not Recruiting

Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia

Role: collaborator

NCT07164976Phase 1Recruiting

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Role: collaborator

NCT02377193Phase 4Completed

Simulect Versus ATG in Sensitized Renal Transplant Patient

Role: collaborator

NCT06303713Phase 1Active Not Recruiting

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

Role: collaborator

NCT02693535Phase 2Recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Role: collaborator

NCT03899155Phase 2Recruiting

Pan Tumor Rollover Study

Role: collaborator

NCT07054346Phase 1Recruiting

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

Role: collaborator

NCT07250087Phase 1Recruiting

Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL

Role: collaborator

NCT07493408Phase 2Not Yet Recruiting

Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML

Role: collaborator

NCT00819546Phase 1Active Not Recruiting

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Role: collaborator

NCT06526299Phase 2Recruiting

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

Role: collaborator

NCT06798558Phase 2Recruiting

Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy

Role: collaborator

NCT07145177Phase 1Recruiting

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

Role: collaborator